Invokana Hcp In New York, LA
Invokana: Type 2 Diabetes Drug
A new treatment option will soon be available to people with type 2 diabetes with the FDA’s approval on Friday of Invokana, a first-in-class medication to lower blood sugar.
Johnson & Johnson’s Invokana (generic name canagliflozin) attacks blood sugar right from the get go, reducing the amount of sugar absorbed from food into the bloodstream. The body then flushes the excess sugar out in the urine.
Invokana Hcp
The medical profession – and analysts – have been paying close attention to Invokana because it lowers blood sugar by a different mechanism than the other diabetes drugs on the market. (Metformin, which I wrote about last week for its anti-cancer and anti-aging benefits, is one of the other popular diabetes medications available.)
Controlling blood sugar is the key to preventing the many side effects caused by diabetes, such as vision loss, nerve damage, kidney damage, and increased risk of heart attack and stroke.
Invokana has been subject to intense scrutiny and speculation because last year a similar drug, Forxiga (generic name dapagliflozin), developed by Bristol-Myers Squibb in partnership with AstraZeneca, was rejected by the FDA. The reason for the rejection was concern over liver damage and cancer risk, specifically breast cancer and bladder cancer. Howver, Forxiga was approved and is in use in Europe.
New York Invokana Attorneys Can Help You
Johnson & Johnson’s application for Invokana cited nine clinical trials involving more than 10,000 patients. The main side effects found were urinary tract infections (UTIs) and yeast infections caused by large amounts of sugar in the urine. (Women prone to UTIs are familiar with this problem.) Forbes’ Matthew Herper reports that this problem could limit Invokana’s sales, according to some analysts’ predictions. People taking Invokana were also found to have the potential to become dizzy or faint when standing up suddenly, giving the drug the potential to cause falls, which can be particularly dangerous to the elderly.
Invokana’s action takes place in the kidneys – it blocks an integral membrane protein, sodium-glucose co-transporter 2, from putting sugar removed by the kidneys back in the bloodstream. Therefore some members of the FDA’s advisory panel expressed concern that Invokana should not be taken by people with moderate to severe kidney disease.
kidneys Johnson & Johnson’s
kidneys Johnson & Johnson’s